PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
A user's six month progress with Pyrilutamide, a hair loss treatment; they experienced positive results such as stopped itching and shedding, as well as regrowth, without any side effects.
The user experienced hair loss possibly due to scalp damage and tried natural treatments with limited success. They reported noticeable hair thickening after using a laser treatment device, suggesting it may be effective, especially for those on finasteride.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.
Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.
The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.
The conversation is about using scalp massaging and Theramid copper peptides for hair loss, with OP reporting slight improvement after four months. OP applies the peptides once daily and massages the scalp twice a day.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.